NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$28.0b

Last Updated

2021/04/10 22:24 UTC

Data Sources

Company Financials +

Executive Summary

Teladoc Health, Inc. provides virtual healthcare services on a business-to-business basis in the United States and internationally. More Details


Snowflake Analysis

High growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has Teladoc Health's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TDOC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: TDOC's weekly volatility (9%) has been stable over the past year.


Market Performance


7 Day Return

-0.8%

TDOC

-0.4%

US Healthcare Services

2.1%

US Market


1 Year Return

23.6%

TDOC

49.9%

US Healthcare Services

56.3%

US Market

Return vs Industry: TDOC underperformed the US Healthcare Services industry which returned 49.6% over the past year.

Return vs Market: TDOC underperformed the US Market which returned 55.3% over the past year.


Shareholder returns

TDOCIndustryMarket
7 Day-0.8%-0.4%2.1%
30 Day-8.8%-3.5%2.4%
90 Day-20.4%-9.3%6.1%
1 Year23.6%23.6%50.3%49.9%59.1%56.3%
3 Year340.5%340.5%140.8%138.9%65.7%55.1%
5 Year1,512.6%1,512.6%228.7%224.3%122.3%97.6%

Long-Term Price Volatility Vs. Market

How volatile is Teladoc Health's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Teladoc Health undervalued compared to its fair value and its price relative to the market?

2.2%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: TDOC ($181.26) is trading below our estimate of fair value ($185.33)

Significantly Below Fair Value: TDOC is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: TDOC is unprofitable, so we can't compare its PE Ratio to the US Healthcare Services industry average.

PE vs Market: TDOC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TDOC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TDOC is good value based on its PB Ratio (1.7x) compared to the US Healthcare Services industry average (5.8x).


Future Growth

How is Teladoc Health forecast to perform in the next 1 to 3 years based on estimates from 26 analysts?

60.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TDOC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: TDOC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: TDOC's is expected to become profitable in the next 3 years.

Revenue vs Market: TDOC's revenue (25.5% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: TDOC's revenue (25.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TDOC's Return on Equity is forecast to be low in 3 years time (1%).


Past Performance

How has Teladoc Health performed over the past 5 years?

-26.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TDOC is currently unprofitable.

Growing Profit Margin: TDOC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TDOC is unprofitable, and losses have increased over the past 5 years at a rate of 26.7% per year.

Accelerating Growth: Unable to compare TDOC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TDOC is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-0.9%).


Return on Equity

High ROE: TDOC has a negative Return on Equity (-3.05%), as it is currently unprofitable.


Financial Health

How is Teladoc Health's financial position?


Financial Position Analysis

Short Term Liabilities: TDOC's short term assets ($1.1B) exceed its short term liabilities ($332.6M).

Long Term Liabilities: TDOC's short term assets ($1.1B) do not cover its long term liabilities ($1.5B).


Debt to Equity History and Analysis

Debt Level: TDOC's debt to equity ratio (9.1%) is considered satisfactory.

Reducing Debt: TDOC's debt to equity ratio has reduced from 14.8% to 9.1% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TDOC has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if TDOC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Teladoc Health current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TDOC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TDOC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TDOC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TDOC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TDOC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average management tenure


CEO

Jason Gorevic (48 yo)

11.83yrs

Tenure

US$7,995,688

Compensation

Mr. Jason N. Gorevic has been Chief Executive Officer at Teladoc Health, Inc. (formerly known as Teladoc, Inc.) (Formerly TelaDoc Medical Services Inc.) since June 2009. Mr. Gorevic serves as Director of D...


CEO Compensation Analysis

Compensation vs Market: Jason's total compensation ($USD8.00M) is about average for companies of similar size in the US market ($USD10.94M).

Compensation vs Earnings: Jason's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: TDOC's management team is seasoned and experienced (5.3 years average tenure).


Board Members

Experienced Board: TDOC's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TDOC insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 111.3%.


Top Shareholders

Company Information

Teladoc Health, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Teladoc Health, Inc.
  • Ticker: TDOC
  • Exchange: NYSE
  • Founded: 2002
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$27.966b
  • Shares outstanding: 154.29m
  • Website: https://www.teladochealth.com

Number of Employees


Location

  • Teladoc Health, Inc.
  • 2 Manhattanville Road
  • Suite 203
  • Purchase
  • New York
  • 10577
  • United States

Listings


Biography

Teladoc Health, Inc. provides virtual healthcare services on a business-to-business basis in the United States and internationally. It covers various clinical conditions, including non-critical, episodic c...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/10 22:24
End of Day Share Price2021/04/09 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.